Research
MYC inhibitor drug targets cancer cells directly and via the immune system
The Brief
- An experimental MYC inhibitor drug targets lung cancer cells directly.
- The same drug makes cancer cells easier for the immune system to target and kill, according to a series of experiments.
- The source reports these findings from experiments and does not describe human trial results.
Why it matters
It suggests MYC inhibition could work through both direct tumour cell killing and immune activation, a combined mechanism relevant to how lung cancer treatments are developed and evaluated.
Who’s affected
- cancer researchers
- oncology drug developers
- lung cancer patients and clinicians following new treatment research
In a series of experiments, researchers have found that an experimental MYC inhibitor drug not only targets lung cancer cells directly but also makes cancer cells easier for the immune system to target and kill.